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Abstract 
Classical swine fever (CSF) is a highly contagious swine disease caused by classical swine fever virus (CSFV). Previously, 
we demonstrated that rAdV‑SFV‑E2, an adenovirus‑delivered, Semliki Forest virus replicon‑vectored marker vaccine 
against CSF, is able to protect pigs against lethal CSFV challenge. From an economical point of view, it will be benefi‑
cial to reduce the minimum effective dose of the vaccine. This study was designed to test the adjuvant effects of Sal-
monella enteritidis‑derived bacterial ghosts (BG) to enhance the protective immunity of rAdV‑SFV‑E2 in pigs. Groups of 
5‑week‑old pigs (n = 4) were immunized intramuscularly twice with 105 median tissue culture infective doses (TCID50) 
rAdV‑SFV‑E2 combined with 1010 colony forming units (CFU) BG, 106 or 105 TCID50 rAdV‑SFV‑E2 alone or 10
10 CFU BG 
alone at an interval of 3 weeks, and challenged with the highly virulent CSFV Shimen strain at 1 week post‑booster 
immunization. The results show that the pigs inoculated with 105 TCID50 rAdV‑SFV‑E2 plus BG or 10
6 TCID50 rAdV‑SFV‑
E2 alone were completely protected from lethal CSFV challenge, in contrast with the pigs vaccinated with 105 TCID50 
rAdV‑SFV‑E2 or BG alone, which displayed partial or no protection following virulent challenge. The data indicate that 
BG are a promising adjuvant to enhance the efficacy of rAdV‑SFV‑E2 and possibly other vaccines.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Classical swine fever (CSF) is one of the most contagious 
diseases and characterized by high fever and high mortal-
ity, resulting in huge economic losses to the pig industry 
[1]. Classical swine fever virus (CSFV), one of the mem-
bers of the Pestivirus genus in the Flaviviridae family, is 
the causative pathogen of CSF. The genome of CSFV is 
a single-stranded, positive-sense RNA of about 12.3  kb, 
which encodes a polyprotein that is processed co- and 
posttranslationally into 12 proteins (Npro-C-Erns-E1-E2-
p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B) [2, 3].
Currently, immunization with modified live vaccines 
(MLV, e.g. C-strain) is a major strategy to control CSF in 
many countries [4]. However, the European Union has 
banned vaccination using traditional CSF MLV against 
CSF since 1990, as antibodies induced by MLV or field 
CSFV strains cannot be distinguished serologically [5]. 
Therefore, developing a safe and effective marker vaccine 
allowing differentiation of infected from vaccinated ani-
mals (DIVA) is very important. To address this issue, we 
developed a marker CSF vaccine rAdV-SFV-E2 based on 
human adenovirus type 5 (HAdV-5)/alphavirus replicon 
chimeric vector. We demonstrate that rAdV-SFV-E2 can 
elicit strong cellular and humoral responses in pigs and 
provide sterile immunity and complete protection against 
lethal CSFV challenge comparable to the C-strain [6, 7]. 
From an economic point of view, it is necessary to reduce 
the minimum effective dose (MED) of the vaccine.
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Co-administration of adjuvants, such as aluminum and 
mineral oil, is an effective method to improve the effi-
cacy of a suboptimal vaccine. Adjuvants can help anti-
gens in activating pathways significantly in the induction 
of innate immunity, predominantly targeting antigen-
presenting cells (APC) and consequently influencing the 
adaptive immune response [8]. Well-characterized bac-
terial ghosts (BG)-based adjuvants have unique advan-
tages. BG are nonliving cell envelope preparations from 
Gram-negative bacteria, devoid of cytoplasmic con-
tents, while their cellular morphology and native sur-
face antigenic structures remain preserved. So they are 
potentially powerful adjuvants due to the presence of 
bacterial membrane components such as lipopolysac-
charides, peptidoglycans and monophosphoryl lipid A 
(MPL) [9]. MPL interacts with toll-like receptor 4 [10], 
induces the production and release of cytokines [11] and 
increases the migration and maturation of dendritic cells 
[12]. Owing to the particulate nature of BG and the fact 
that they contain many well-known immune-stimulating 
compounds, BG have the potential to enhance immune 
responses to various antigens [13]. Therefore, we hypoth-
esize that rAdV-SFV-E2 with BG can provide a better 
protection against CSF in pigs.
The present study was aimed at evaluating the adju-
vant effects of BG to enhance the protective immunity of 
rAdV-SFV-E2 in pigs.
Materials and methods
Bacterial ghost adjuvant, vaccines and viruses
The Salmonella enteritidis-derived BG adjuvant was pro-
duced by controlled expression of the modified lysis gene 
E (mE) from bacteriophage ΦX174 [14]. Briefly, S. ente-
ritidis DH091 harboring the recombinant bacteriolytic 
plasmid pBV-mE expressing the mE that is able to lyse 
the bacteria when induced at 42  °C, was cultured to an 
OD600nm of 1.0 at 37 °C. Then the culturing temperature 
was raised to 42  °C for mE expression, resulting in lysis 
of the bacteria. After 1 h, when the lysis curve started to 
decline, 10 μL of the cell suspension was spread onto LB 
plates containing ampicillin, followed by a 12-h incuba-
tion at 37 °C. Viable colonies were determined as colony 
forming units (CFU)/mL. The OD600nm was measured 
every 15  min till no further decline in OD600nm. After 
lysis, the BG were harvested by centrifugation (4000 × g 
for 10  min), washed with PBS (pH 7.2), suspended in 
20  mL of sterile distilled water, lyophilized and stored 
at −20  °C. rAdV-SFV-E2 is an adenovirus-delivered, 
alphavirus replicon-vectored vaccine encoding the E2 
glycoprotein of CSFV [6]. The highly virulent CSFV Shi-
men strain [7] maintained at Harbin Veterinary Research 
Institute (HVRI) was used for challenge.
Animals
Twenty 5-week-old cross-bred weanling piglets, free of 
CSFV-specific antibodies and antigens, were raised in 
the animal facility at HVRI. All experimental procedures 
involving animals were approved by the Experimental 
Animal Ethics Committee of HVRI.
Immunization‑challenge experiment
The piglets were randomly divided into five groups of 
four animals each. Groups A and C were respectively 
vaccinated with 106 TCID50 and 105 TCID50 rAdV-SFV-
E2 alone; Group B were co-immunized intramuscu-
larly with 105 TCID50 rAdV-SFV-E2 and 1010 CFU BG; 
Groups D and E were injected intramuscularly with 
1010 CFU BG and DMEM (2  mL), respectively, serving 
as controls. Three weeks later, all the pigs were given a 
booster immunization with the same vaccine, dose and 
route of administration. All the pigs were challenged 
intramuscularly with 106 TCID50 CSFV Shimen strain 
1 week post-booster immunization. Following challenge, 
the rectal temperature and clinical signs were recorded 
every day. All the pigs were euthanized at 15  days 
post-challenge (dpc). The tissues from all the pigs were 
subjected to pathological examinations as described pre-
viously [15].
Serological assays
Serum samples were collected at different time points 
post-immunization. The presence of the E2-specific anti-
bodies in samples were tested using the IDEXX Herd-
Chek* CSFV antibody test kit (IDEXX Laboratories, 
Shiphol-Rijk, The Netherlands).
To test the level of CSFV-specific neutralizing antibod-
ies (NAbs), a serum-virus neutralization test (SVNT) was 
carried out in 96-well flat-bottom microtiter plates (Cor-
ing, USA) as described previously [16].
Real‑time RT‑PCR
The total RNA was extracted from EDTA-treated blood 
samples collected at different days after challenge, and 
detection of CSFV RNA was performed by real-time RT-
PCR with a CSFV-specific probe (5′-FAM-AGG ACT 
AGC AAA CGG AGG GAC TAG CCG-TAMRA-3′) and 
a primer pair (5′-GAA CTG GGC TAG CCA TG-3′ and 
5′-ACT GTC CTG TAC TCA GGA C-3′) [17].
Pathology
All surviving pigs were euthanized at 15 dpc. Various 
organs (spleen, kidney, tonsils, lymph nodes and blad-
der) were collected and subjected to pathological and 
histopathological examinations as described previously 
[6, 18].
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Statistical analysis
Statistical analysis was conducted using the SPSS 14.0 
software. One-way ANOVA followed by Duncan’s mul-
tiple-range tests were used to compare the parameters 
among the different groups.
Results
Antibody production
E2-specific antibodies and NAbs were tested by block-
ing ELISA and SVNT following vaccination and chal-
lenge. The E2-specific antibodies were first detected in all 
the pigs in Group B (105 TCID50 rAdV-SFV-E2 plus 1010 
CFU BG) at 1 week post-booster immunization, with the 
mean antibody blocking rate of 59.91%. Most pigs (3/4) in 
Group A (106 TCID50 rAdV-SFV-E2 alone) seroconverted 
at 1  week post-booster immunization. After challenge, 
the anti-E2 antibodies in Groups A and B decreased tran-
siently at 0–3 dpc and then increased sharply after 3 dpc, 
and the antibody titers peaked at 9  dpc, with the mean 
antibody blocking rates of about 80%. The E2-specific 
antibodies were undetectable in Group C (105 TCID50 
rAdV-SFV-E2 alone) prior to challenge and detected at 
9 dpc, with the mean antibody blocking rates of 40.96%. 
As expected, no E2-specific antibody was detected in 
Groups D (1010 CFU BG alone) and E (DMEM) through-
out the experiment. There was a significant difference 
at 0 and 3 dpc (P < 0.05), a very significant difference at 
6 dpc (P < 0.001) between Groups B and C, and no sig-
nificant difference in antibody titers between Groups A 
and B during the experiment (P > 0.05) (Figure 1).
Based on SVNT, anti-CSFV NAbs were also tested. At 
21  days post-vaccination (dpv), anti-CSFV NAbs were 
detected in Group B and the mean neutralization titers 
were 1:14. The neutralization titers rose to a peak at 
28 dpv (7 days post-booster immunization), with 1:122 in 
Group A, 1:164 in Group B. Following virulent challenge, 
anti-CSFV NAbs levels increased remarkably after a tran-
sient slight decrease in Group A or B, and at 9 dpc, with 
mean neutralization titers of 1:841 for Group A, 1:612 for 
Group B. In Group C, anti-CSFV NAbs were detected at 
9 dpc, with mean neutralization titers of 1:194. No neu-
tralizing titers were detectable in Groups D and E. There 
was a significant difference in anti-CSFV NAbs levels 
between Groups B and C at 9 dpc (P < 0.05) (Table 1).
Clinical protection of vaccinated pigs from virulent CSFV 
challenge
No adverse reactions were observed in any pigs fol-
lowing immunization. Following virulent challenge, 
Figure 1 Detection of serum antibodies in immunized pigs 
by blocking ELISA. Five groups of pigs (n = 4) were immunized 
and challenged as described in the “Materials and methods” section. 
Serum samples were taken at 21 days post‑immunization and 0 
(7 days post‑booster immunization), 3, 6, 9 and 12 days post‑chal‑
lenge and tested for CSFV‑specific NAbs. Standard deviations were 
shown as error bars. *Significant difference between Groups B and 
C (P < 0.05); **very significant difference between Groups B and C 
(P < 0.001); CFU: colony forming units.
Table 1 CSFV-specific neutralizing antibodies in pigs following lethal CSFV challenge
Five groups of pigs (n = 4) were immunized and challenged as described in the “Materials and methods” section. Serum samples were collected at different times 
following immunization and challenge and subjected to detection of anti-CSFV neutralizing antibody titers by serum–virus neutralization test. The diluted sera were 
mixed with equal volume of 200 TCID50 CSFV Shimen strain and incubated for 60 min at 37 °C. The serum–virus mixtures were inoculated to confluent PK-15 cells 
cultured in 96-well plates and incubated for 60 min at 37 °C. The inoculated cells were then incubated for 72 h at 37 °C. IFA was performed as described previously [6]. 
The cells were examined under a fluorescence microscope, and the titers of CSFV-specific neutralizing antibodies were determined and expressed as the reciprocal of 
the highest dilution at which infection of the PK-15 cells was inhibited in 50% of the culture wells. 
* Significant difference between groups B and C (P < 0.05).
CFU: colony forming units.
Groups Days post‑immunization (days post‑challenge)
0 21 28 (0) 31 (3) 34 (6) 37 (9)
A: rAdV‑SFV‑E2 (106 TCID50) <10 <10 122 ± 52 62 ± 9 699 ± 88 841 ± 258
B: rAdV‑SFV‑E2 (105 TCID50) + BG (1010 CFU) <10 14 ± 2 164 ± 39 147 ± 65 484 ± 66 612 ± 89*
C: rAdV‑SFV‑E2 (105 TCID50) <10 <10 <10 <10 <10 194 ± 83
D: BG (1010 CFU) <10 <10 <10 <10 <10 <10
E: DMEM <10 <10 <10 <10 <10 <10
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no clinical symptoms were observed in Group A 
or B. Three out of four pigs in Group C exhibited a 
short-term fever (ranging from 40.5 to 42  °C), and 
all returned to normal 2–5  days later and survived at 
15 dpc. One pig in Group C and all the pigs in Groups 
D and E showed typical CSF clinical signs, such as 
fever, inappetence, depression, chill, constipation, pros-
tration and incoordination, followed by diarrhea, loco-
motorataxia and posterior paresis from 3  dpc to the 
end of the experiment. The fever frequencies in Groups 
D (27/46) and E (27/44) were the highest, followed by 
Group C (14/50) (Table 2).
Virological protection of vaccinated pigs from virulent 
CSFV challenge
Viral RNA was undetectable in Group A or B. Low-level 
viral RNA (about 103  copies/μL) was detected in some 
pigs (2/4) in Group C at 6, 9 and 12 dpc. In Groups D 
and E, viral RNA loads higher than 103  copies/μL were 
detected from 6 dpc to death (Table 3).
Table 2 Clinical outcome of the immunized pigs following virulent challenge
Five groups of pigs (n = 4) were immunized and challenged as described in the “Materials and methods” section. Following challenge, the clinical signs and rectal 
temperatures were recorded daily. Fever is defined as rectal temperature ≥40.5 °C.
– no fever, CFU: colony forming units.
a Numbers of pigs showing fever/total numbers of pigs in each group.
b Total days with any pig showing fever/total days of monitored for all the pigs in a group following virulent challenge.
Groups Days to fever onset Fever ratea Fever frequencyb Survival rate
A: rAdV‑SFV‑E2 (106 TCID50) – 0/4 0/60 4/4
B: rAdV‑SFV‑E2 (105 TCID50) + BG (1010 CFU) – 0/4 0/60 4/4
C: rAdV‑SFV‑E2 (105 TCID50) 3 3/4 14/50 3/4
D: BG (1010 CFU) 3 4/4 27/46 0/4
E: DMEM 3 4/4 27/44 0/4
Table 3 Detection of viral RNA in whole blood samples from immunized pigs after virulent challenge by real-time RT-PCR
Five groups of pigs (n = 4) were immunized and challenged as described in the “Materials and methods”. Whole blood samples were collected at days 0, 3, 6, 9 and 12 
post-challenge. CSFV RNA was extracted and quantified by a real-time RT-PCR described previously [17].
– not detectable, / died, CFU: colony forming units.
Groups Pig No. Days post‑challenge
0 3 6 9 12
A: rAdV‑SFV‑E2 (106 TCID50) A1 – – – – –
A2 – – – – –
A3 – – – – –
A4 – – – – –
B: rAdV‑SFV‑E2 (105 TCID50) + BG (1010 CFU) B1 – – – – –
B2 – – – – –
B3 – – – – –
B4 – – – – –
C: rAdV‑SFV‑E2 (105 TCID50) C1 – – – – –
C2 – – 1.49 × 104 3.70 × 103 /
C3 – – – – –
C4 – – 2.70 × 103 4.40 × 103 1.97 × 102
D: BG (1010 CFU) D1 – – 2.35 × 104 5.04 × 104 /
D2 – – 4.86 × 104 2.43 × 104 2.55 × 105
D3 – – 5.04 × 105 6.96 × 105 /
D4 – – 3.44 × 104 6.81 × 103 1.68 × 104
E: DMEM E1 – – 1.31 × 104 2.67 × 104 /
E2 – – 4.21 × 105 4.70 × 104 9.08 × 104
E3 – – 9.76 × 104 6.55 × 105 /
E4 – – 3.06 × 105 3.92 × 103 /
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Pathological protection of vaccinated pigs from lethal 
CSFV challenge
At 15  dpc, all surviving pigs were euthanized and sub-
jected to pathological and histopathological examina-
tions. All the pigs in Groups A and B did not show any 
pathological changes. Most pigs (3/4) in Group C showed 
mild lesions (including infarcts in the spleen, slight hem-
orrhages in the lymph nodes and necrotic foci in the ton-
sils). Similar severe pathological changes were observed 
in one pig of Group C and all the pigs of Groups D and 
E, including infarcts in the spleen, massive petechiae 
in the kidney and bladder, hemorrhages with necrotic 
foci in the tonsils, enlargement and hemorrhage of the 
lymph nodes and button-like ulcers in the ileocecal valve 
(Figure 2).
No histopathological changes were observed for pigs 
in Groups A and B. The pigs in Group C displayed slight 
to moderate histopathological changes in some tis-
sues, including focal necrosis in the splenic parenchyma 
and depletion of lymphocytes in the white pulp in the 
spleen and hemorrhages in the lymph nodes. The pigs in 
Groups D and E displayed similar severe histopathologi-
cal changes in most tissues, including depleted lymphoid 
follicles and hemorrhages in the lymph nodes and tonsils, 
diffuse hemorrhages throughout the splenic parenchyma 
and depletion of lymphocytes in the white pulp in the 
spleen, hemorrhages in the interstitial spaces in the kid-
ney and diffuse hemorrhages in the bladder (Figure 3).
Discussion
In this study, the efficacy of rAdV-SFV-E2 in combina-
tion with BG was evaluated. The results show that pigs 
injected with 105 TCID50 rAdV-SFV-E2 plus 1010 CFU 
BG provided complete protection against lethal CSFV 
challenge and the efficacy was comparable to 106 TCID50 
rAdV-SFV-E2, which indicates that BG can decrease the 
effective immunization dose of rAdV-SFV-E2 by at least 
10-fold.
Adjuvants, such as microbial proteins or carbohy-
drates may activate APC and induce specific immune 
Figure 2 Representative pathological changes of immunized pigs challenged with CSFV Shimen strain. Five groups of pigs (n = 4) were 
immunized and challenged as described in the “Materials and methods” section. At 15 days post‑challenge (dpc), all surviving pigs were euthanized 
and different tissues (spleen, kidney, tonsils, lymph nodes and bladder) were collected and pathological examinations performed. CFU: colony form‑
ing units.
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responses [19]. BG have the same potential because of 
their adjuvant components [20, 21]. A recent study has 
demonstrated that internalization of BG by porcine APC 
leads to enhanced expression of antigen-presenting mol-
ecules on the surface of APC and significantly increases 
the antigen-presenting capacity of APC [20]. Therefore, 
more memory B cells were generated following immu-
nization with rAdV-SFV-E2 plus BG than rAdV-SFV-E2 
alone, since more antigens were presented to B cells by 
activated APC. Another possible mechanism might be 
the effective delivery of rAdV-SFV-E2 by BG, since BG 
can function as carriers of protein antigens, drugs and a 
high loading capacity for DNA [9, 21]. Thus, immuniza-
tion with BG-adjuvanted rAdV-SFV-E2 induced higher 
E2-specific antibodies and NAbs than rAdV-SFV-E2 
alone after booster immunization (Figure 1; Table 1).
No significant difference in serum interferon γ (IFN-
γ) and interleukin 4 (IL-4) was found between Groups 
B (105 TCID50 rAdV-SFV-E2 plus 1010 CFU BG) and C 
(105 TCID50 rAdV-SFV-E2) (data not shown). Therefore, 
Figure 3 Representative histopathological changes in pigs challenged with CSFV Shimen strain. Five groups of pigs (n = 4) were immu‑
nized and challenged as described in the “Materials and methods” section. At 15 days post‑challenge (dpc), various tissues (spleen, kidney, tonsils, 
lymph nodes and bladder) were collected from the challenged animals, fixed with buffered 4% formalin and subsequently embedded in paraffin 
wax. Tissue sections (around 4‑μm thick) were prepared and stained with hematoxylin and eosin for histopathological examinations. In Groups D 
and E, severe hemorrhages in the lymph nodes, tonsils, spleen, kidney and bladder were indicated as arrows; in Group C, slight to moderate histo‑
pathological changes were found in some tissues, such as focal necrosis in the splenic parenchyma (arrow) and depletion of lymphocytes (arrow) in 
the white pulp in the spleen and hemorrhages (arrow) in the lymph nodes. All the pigs in Group A or B did not show any histopathological changes. 
CFU: colony forming units. Bars 50 μm.
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it is necessary to evaluate cellular immune responses in 
details in future work, especially the CSFV-specific CD8+ 
cytotoxic T lymphocytes, which represent an important 
defense mechanism in the elimination of cells infected 
by CSFV [5, 22, 23]. In this study, we also found that 
some pigs immunized with BG displayed transient aller-
gic reactions. In the following experiments, different 
amounts of the BG will be evaluated and compared with 
several commonly used adjuvants regarding the enhance-
ment of the protective immunity of rAdV-SFV-E2.
In conclusion, the BG adjuvant can significantly 
enhance the protective immunity induced by the chi-
meric vector-based vaccine rAdV-SFV-E2 against CSF 
in pigs and it may be a promising adjuvant for other 
vaccines.
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